MANGOCEUTICALS, INC. (MGRX): Nasdaq/NYSE listing notice — Mangoceuticals receives Nasdaq bid-price deficiency notice; 180 days to cure

MANGOCEUTICALS, INC.

Received Nasdaq notice on Oct 30, 2023 for failing $1.00 minimum bid price for 30 consecutive business days.
Has until April 29, 2024 to regain compliance by closing at $1.00+ for 10 consecutive days.
If not cured, may qualify for a second 180-day cure period if other listing criteria are met.
Company plans to monitor bid price and may consider a reverse stock split to regain compliance.
No immediate impact on Nasdaq listing; delisting risk if deficiency not cured within timelines.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

MANGOCEUTICALS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

October 30, 2023, Mangoceuticals, Inc. (the “Company”) received written notice (the “ Notification Letter ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if

View on SEC.gov

Browse all listing & compliance notices →

MANGOCEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-038998

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.